Forecasting a virus's next move: antiGen shortlists mutations from the evolutionary tree, and Germinal Multi redesigns antibodies against them
Monoclonal antibodies were an important early tool against COVID-19, but they lost effect as SARS-CoV-2 mutated, and screening for antibodies that hold across variants struggles to keep up. antiGen learns from mutations already made along a virus's phylogenetic tree rather than from sequences alone, using roughly half a million parameters to forecast plausible next mutations; Germinal Multi tests one antibody design against several versions of a target at once on a computer. Combined, they redesigned BD55-1205, which neutralized XFG but not XFG-Next, into X51, which blocked infection by both in laboratory tests.